Related Experiment Video
Updated: Jul 16, 2026
05:47
Simulation of a Scaled Assembly Process with Collaboration of a Robotic Arm and Monitoring through a Vision System for Quality Control
Published on: August 29, 2025
The VELYS robotic-assisted solution: a strategic technology evaluation informed through scoping review
Scott R Morrison1,2,3, Andrew J Hall1,2,3, Nick D Clement1,2,4
1SCOTTISH Network, Golden Jubilee University National Hospital, Clydebank, UK.
Computer Assisted Surgery (Abingdon, England)
|July 14, 2026
Summary
Robot-assisted surgery (RAS) using the VELYS Robotic-Assisted Solution (VRAS) shows promise for knee arthroplasty. However, more high-quality evidence is needed to confirm its long-term clinical and economic value.
Area of Science:
- Orthopedic surgery
- Robotics in medicine
- Health technology assessment
Background:
- Robot-assisted surgery (RAS) is growing in arthroplasty, but evidence is limited.
- Different RAS systems require specific evaluations.
- The VELYS Robotic-Assisted Solution (VRAS) is an imageless, semi-active robotic platform for knee arthroplasty.
Purpose of the Study:
- To conduct a structured evaluation of VRAS.
- To align the assessment with the National Institute for Health and Care Excellence Early Value Assessment (EVA) framework.
- To propose a roadmap for future evidence generation for VRAS.
Main Methods:
- Systematic literature search identifying 16 studies, mostly retrospective.
- Synthesis of findings using a Strengths, Weaknesses, Opportunities, and Threats (SWOT) framework.
- Analysis to inform strategic recommendations for VRAS evidence generation.
Main Results:
- VRAS strengths: imageless, integrates with implants, short learning curve, potential for improved short-term outcomes.
- VRAS weaknesses: immature evidence base, lack of long-term data, no haptic feedback.
- Opportunities: reduced costs with imageless workflow; Threats: high capital costs, competition, unmet evidence requirements.
Conclusions:
- Evidence for patient-reported outcomes, cost-effectiveness, and long-term benefits of VRAS is insufficient.
- High-quality, powered studies and health-economic analyses are crucial.
- Longitudinal, registry-linked studies are needed to establish VRAS's clinical and economic value within the EVA framework.
